Trapolmin Duo Controlled Release Tablet 2.5/1000 mg
Linagliptin Micronized 2.5mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Daewon Biotech Co., Ltd.
MFDS item code 202400631 · Approved 2024.03.25
Improvement of glycemic control in type 2 diabetes mellitus
This medication is prescribed to help patients with type 2 diabetes control their blood sugar by using linagliptin and metformin together. It is administered in conjunction with dietary adjustments and exercise therapy to effectively improve blood sugar levels. It supports patients in managing their blood sugar more effectively.
In antidiabetic therapy, the dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 5 mg and metformin hydrochloride extended-release 2000 mg. This drug should be taken once daily with a meal, preferably with the evening meal. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. To maintain the extended-release properties, swallow this drug whole; do not split, crush, grind, or chew it. Take 1 tablet of this drug 5/1000 mg extended-release tablet once daily. Patients taking this drug 2.5/750 mg extended-release tablet or 2.5/1000 mg extended-release tablet should take 2 tablets together once daily. 1. If the patient is not currently being treated with metformin: The initial dose of this drug is a total daily dose of linagliptin 5 mg and metformin hydrochloride 1000 mg; the dose of metformin hydrochloride may be gradually increased up to the maximum recommended daily dose of 2000 mg. 2. If the patient is being treated with metformin - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the initial dose of this drug is a total daily dose of linagliptin 5 mg and the patient's current dose of metformin hydrochloride. - For patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea or metformin and insulin, the initial dose of this drug should be considered as a total daily dose of linagliptin 5mg and a dose of metformin hydrochloride similar to the patient's current dose. When this drug is administered concomitantly with insulin or a sulfonylurea, a reduction in the dose of insulin or the sulfonylurea may be necessary to reduce the risk of hypoglycemia. - When switching from an immediate-release metformin formulation to an extended-release formulation, glycemic control should be closely monitored, and dosage adjustments should be made as appropriate if necessary. -When switching from combination therapy with linagliptin and extended-release metformin to this drug, the dose of this drug should be the current doses of linagliptin and extended-release metformin hydrochloride. Special populations Renal impairment Because dosage adjustment according to renal function is necessary, assessment of renal function is recommended before and periodically after administration of this drug. No dosage adjustment of this drug is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73m2]. In patients with moderate renal impairment (CKD stage 3A), with creatinine clearance (CrCl) of 45mL/min or more and less than 60mL/min, or estimated glomerular filtration rate (eGFR) of 45mL/min/1.73m2 or more and less than 60mL/min/1.73m2, this drug may be used with adjustment of the metformin hydrochloride dose as follows, provided it is well tolerated and the patient has no other conditions that may increase the risk of lactic acidosis. The starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily; therefore, treatment should not be initiated with this drug. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to less than 45mL/min or estimated glomerular filtration rate (eGFR) decreases to less than 45mL/min/1.73m2, this drug must be discontinued immediately.
This medication can rarely cause severe lactic acidosis or hypoglycemia, so caution is necessary. It should not be used in cases of allergies to the components included in this medication, or in individuals with type 1 diabetes, lactic acidosis, diabetic ketoacidosis, severe renal impairment, acute heart disease, etc. Use of this medication should also be avoided in acute situations that may affect renal function, such as severe infections, dehydration, severe trauma, shock, and administration of radiocontrast agents containing iodine. Patients with liver dysfunction, acute alcohol intoxication, malnutrition, or acute and unstable heart failure should not use this medication. It is advisable to avoid this drug during pregnancy or if there's a risk of placental dysfunction or pre-eclampsia. Since there is a risk of hypoglycemia, dosage adjustment and caution are needed when used in combination with sulfonylureas or insulin. Lactic acidosis, although rare, is a very serious side effect associated with worsening renal function, cardiopulmonary conditions, and sepsis, so symptoms should be reported to a physician immediately if they occur. Since this medication is mainly excreted via the kidneys, it is important to regularly test kidney function and discontinue or adjust dosage if kidney function is impaired. Patients with weakened heart function should use this medication cautiously, and it should be discontinued for a certain period before and after the administration of radiocontrast agents containing iodine. It is also necessary to discontinue this medication for a certain period before and after surgery. This drug may cause skin conditions such as pancreatitis or blistering dermatitis, so if symptoms occur, immediate consultation with medical professionals is necessary. Long-term use may lead to vitamin B12 deficiency; therefore, blood levels of vitamin B12 should be checked and supplemented if necessary. This medication should be swallowed whole without crushing or chewing, and it is normal for the shell of the tablet to appear in stool. There can be interactions with other medications, so caution is especially necessary when used with drugs that affect renal function. It is recommended to avoid use during pregnancy or breastfeeding. Safety and efficacy in pediatric patients have not been established, and elderly patients may require dosage adjustments and regular monitoring of kidney function due to the risk of renal impairment. In case of overdose, gastrointestinal disturbances and lactic acidosis may occur, so if suspected, immediate medical attention should be sought. This medication should be kept out of reach of children, away from moisture, and should not be transferred to other containers.
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to air and moisture, so it must be stored in a tightly sealed container. It should be kept at room temperature between 1 degree and 30 degrees Celsius. This will help maintain the effectiveness of the medication for a long time.
Pink, oval-shaped, bilaterally convex controlled-release film-coated tablet
30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Linagliptin Micronized 2.5mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Daewon Biotech Co., Ltd.
CombinationLinagliptin Micronized 5mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
Linagliptin Micronized 5mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Daewon Bio Tech Co., Ltd.
CombinationLinagliptin Micronized 2.5mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 757.5mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationLinagliptin Micronized 2.5mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
Linagliptin Micronized 2.5mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 757.5mg
Tablet · Prescription medication · Combination
Daewon Biotech Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.